Top Pharmaceutical Companies in Chicago, IL (51)
Our mission is to improve health outcomes through behavior change at the point of care and beyond. Every day, people make choices that shape their health, and at PatientPoint, we strive to support those decisions with the right information delivered at the right time. We're proud to power the largest network of digital devices in doctor's offices across the country —...
PatientPoint's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Advent International agreed on August 25, 2025 to acquire PatientPoint, with reporting at more than $1.4B, providing external validation and resources to accelerate expansion. This backing is positioned to support network growth and product innovation.
Product Line Growth: In March 2026 PatientPoint launched programmatic buying (Health Audiences) and a Consumer Health Network aimed at CPG/OTC brands, expanding how advertisers can buy and who the company serves. These additions broaden monetization beyond traditional life‑sciences sponsors.
Strong Market Position & Advantage: PatientPoint reports a nationwide footprint in 30,000+ physician offices and 125,000 providers, and in April 2026 received expanded Media Rating Council accreditation across its full digital screen network. This scale and third‑party validation bolster credibility for national buys.
Kalderos is a data infrastructure and analytics company that’s solving challenges around drug discounts in the U.S. healthcare system. Through platform technology and big data, our team is delivering smart solutions that enable healthcare stakeholders to collaborate with greater transparency and trust. We’re passionate about our mission to take on the most stubborn challenges in healthcare. We also know that...
Kalderos's Top Stability & Growth Strengths
Strategic Partnerships: The acquisition by Model N positions Kalderos’s 340B and gross-to-net capabilities inside a larger life-sciences revenue platform, implying broader distribution and customer access. Integration of the Truzo claims-level visibility into Model N’s suite signals strategic value and scale-up potential.
Strong Revenue Growth: Company materials state revenue more than doubled two years in a row leading into 2023, alongside expanding customers and team. These signals point to strong pre-acquisition traction that can be leveraged under Model N.
Market Expansion: 340B drug purchases reached roughly $66.3B in 2023, indicating a large and expanding market the combined offering serves. This category tailwind supports ongoing demand for discount-management and gross-to-net solutions.
We are a group of dedicated scientific, medical, and business professionals who are driven to find treatments and cures to a variety of diseases. By attacking the disease directly with our novel nanoparticle-based technologies and working strategically with our medical and scientific partners we seek to provide treatments and cures previously unavailable to doctors and their patients.
ClearTrial software makes the planning, forecasting, and tracking of clinical project and financial performance faster and more accurate. The world’s leading biopharmaceutical and medical device companies rely on ClearTrial to gain internal and supplier efficiencies, compress cycle-times, and reduce costs.In 2011, ClearTrial was named by Gartner Group as one of the Top 5 “Cool Vendors” in the Life Sciences industry,...
The National MS Society is a non-profit organization dedicated to curing multiple sclerosis while empowering people affected by the disease to live their best lives through research, education, and support.
Sterigenics, a Sotera Health company, is a global leader in comprehensive sterilization services for the medical device, pharmaceutical, food safety and advanced applications markets. With our industry recognized scientific and technological expertise we help to ensure the safety of millions of patients and healthcare practitioners around the world every year. We offer our customers a complete range of outsourced terminal...
Kashiv BioSciences is a fully-integrated biopharmaceutical company with global R&D, clinical, manufacturing, regulatory, and IP capabilities, focusing on developing and manufacturing biosimilars and complex peptide medicines to improve access to important therapies.
Amerita, Inc. is a specialty infusion company focused on providing complex pharmaceutical products and clinical services to patients outside of the hospital. This market is expanding rapidly and is driven by increasing healthcare costs that are moving patients into the most cost-effective delivery settings, a growing bio-pharmaceutical pipeline of
ALTATHERA Pharmaceuticals is a commercial-stage specialty pharmaceutical company focused on critical care and alternative therapeutics for unmet medical needs of patients with severe, and often rare, disorders for which few effective treatments are available. ALTATHERA's commitment to improving patients
Lundbeck is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research and today our products are available in more than 100 countries. We are tirelessly dedicated to restoring brain health, so every person can be their best. The neuroscience market is on a growth trajectory. We see...
Founded in 2001, cGMP Consulting Inc. has strived to help our clients adopt new technologies and ensure that changes to your processes are compliant with current Good Manufacturing Practices (cGMP). Our experienced engineering and quality assurance consultants have helped many industry leading companies identify and remediate gaps, support international pharmaceutical manufacturing, and implement cGMP requirements.
The future of health is fast paced and complex, demanding a different approach. Established in 2001, our 1,300+ healthcare experts, combine their knowledge and expertise across our 4 core disciplines — Consulting; Medical; Marketing; and Policy, Access, Value, & Evidence. Working across the product and service lifecycle, from R&D to post launch, we engage our collective force to solve the complex...
Caprion Biosciences was a leading provider of proteomics and immune monitoring services to the pharmaceutical and biotechnology industry, specializing in advanced immunology and proteomics services. It has since rebranded to CellCarta, a global contract research organization.
EVERSANA is the provider of global services to the life science industry.
EVERSANA's Top Stability & Growth Strengths
Strong Market Position & Advantage: Evidence indicates EVERSANA maintains a strong market position through its integrated, end-to-end commercialization model and a top-tier agency network. Feedback suggests exclusive launch mandates and consistent MM+M top‑10 agency rankings reinforce this competitive advantage.
Innovation-Driven Growth: Feedback suggests the company is investing in AI-enabled and software-driven offerings, including an AI Accelerator, an AI-powered marketing agency, and Waltz Health’s drug-pricing/access technology. These moves position the platform for tech-enabled growth across access, pricing, and omnichannel execution.
Market Expansion: Evidence indicates EVERSANA is expanding capacity and reach through a large new distribution center and a merger that extends influence with payers and employers. Ongoing commercialization wins and partnerships show continued entry into adjacent access and pricing markets.
Nitta Gelatin NA, Inc. manufactures a wide range of food, pharmaceutical, and technical grade gelatins and collagen-related products.
At Astellas, we strive to be a cutting-edge, value-driven life science innovator. This means working at the forefront of healthcare change to turn innovative science into the best outcomes for patients. Operating in approximately 70 countries with more than 14,000 employees, we are relentless in our pursuit of scientific progress and in tackling unmet medical needs. Visit our Global Astellas...
Astellas Pharma's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue reached a record level in FY2024 with double‑digit year‑over‑year growth, and management raised FY2025 guidance after continued momentum through the first nine months. Company updates attribute this to strong contributions from “Strategic Brands” including PADCEV, VYLOY, VEOZAH, IZERVAY and sustained XTANDI demand.
Profitability: Core operating profit increased markedly faster than sales in FY2025 year‑to‑date, reflecting margin expansion. Management links improvement to mix benefits from strategic brands and cost programs such as the Sustainable Margin Transformation initiative.
Strong Market Position & Advantage: Astellas demonstrates category leadership in niches—XTANDI in prostate cancer and PADCEV + Keytruda setting a new first‑line standard in advanced urothelial cancer with later perioperative expansion. First‑in‑class positions in CLDN18.2 gastric cancer (VYLOY) and non‑hormonal menopause therapy (VEOZAH) further strengthen its competitive footing.
NOCD provides online therapy for obsessive-compulsive disorder (OCD), one of the most severe, prevalent, and misunderstood mental health conditions. Inside the NOCD telehealth platform, people with can-do live, face-to-face video therapy sessions with licensed therapists that specialize in OCD, as well as get 24/7 support between sessions.
A global leader in developing and producing responsible packaging for food, beverage, pharma, medical, home- and personal-care, and other products. Amcor works with leading companies around the world to protect their products and the people who rely on them, differentiate brands, and improve supply chains through a range of flexible and rigid packaging, specialty cartons, closures, and services. The company...
Eli Lilly and Company engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment. For more than a century, we have stayed true to a core set of values – excellence, integrity, and respect for people – that guide us in all we do: discovering medicines that meet real needs, improving the understanding and management of...
Eli Lilly and Company's Top Stability & Growth Strengths
Strong Market Position & Advantage: By market value and category leadership in incretins, Lilly sits at or near the top of global pharma. Mounjaro/Zepbound are redefining obesity/diabetes, with Mounjaro becoming the world’s best‑selling prescription drug in early 2026.
Strong Revenue Growth: Results show outsized, volume-led acceleration, with Q1 2026 revenue reaching $19.8B. Management also raised 2026 sales guidance to about $82–$85B after very strong 2025 growth.
Innovation-Driven Growth: Recent approvals and pipeline progress beyond metabolic disease add new growth pillars. The FDA approval of Kisunla (donanemab) in 2024 and advancement of oral GLP‑1 programs broaden the portfolio.
Frontage Laboratories, Inc. is a CRO that provides integrated, science-driven, product development services throughout the drug discovery and development process to enable pharmaceutical and biotechnology companies to achieve their development goals. Comprehensive services include drug metabolism and pharmacokinetics, analytical testing and formulation development, preclinical and clinical trial material manufacturing, bioanalysis, preclinical safety and toxicology assessment and early phase clinical studies....
Frontage Laboratories, Inc's Top Stability & Growth Strengths
Market Expansion: Recent announcements describe expansion of early‑phase clinical capabilities in 2026 alongside new and enlarged sites in Exton, Pennsylvania and Europe, indicating broader geographic reach and capacity. Acquisitions and a rising backlog/future contracted revenue further point to continuing expansion into additional markets and regions.
Product Line Growth: New GMP CRDMO capacity came online with a 46,300‑sq‑ft facility opened in 2025 and fully validated by late 2025, adding nine GMP suites and related labs. The 2026 acquisition of a CAP‑accredited central lab in China and added early‑phase clinical capabilities broaden the service portfolio.
Strong Revenue Growth: Recent interim results show first‑half 2026 revenue up 17.1% year over year with net profit more than doubling, signaling a rebound from prior softness. Purchase orders/backlog also increased versus prior periods, supporting near‑term top‑line momentum.
